NCT04067752View on ClinicalTrials.gov

Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

May 15, 2024

Study Completion Date

May 20, 2024

Conditions
End-stage Renal Disease
Interventions
OTHER

high dialysate sodium concentration (138 mEq/L)

high dialysate sodium concentration (138 mEq/L)

OTHER

Low dialysate sodium concentration

low dialysate sodium concentration (132 mEq/L)

Trial Locations (2)

37232

Vanderbilt University Medical center, Nashville

37212-2637

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville

All Listed Sponsors
lead

VA Office of Research and Development

FED